Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793)
McGinley J, L’Italien G, Thiry A, Croop R, Coric V, Lipton R. Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1793.Peer-Reviewed Original Research